Global Liquid Biopsy Products Market on Growth Trajectory, Poised to Exceed USD 11.45 Billion by 2031

QY Research has recently published a report, titled "Liquid Biopsy Products Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". The global Liquid Biopsy Products market is comprehensively analyzed in the report with the main objective of providing accurate market data and useful recommendations to help players to gain strong growth in future. The report is compiled by subject matter experts and experienced market analysts, which makes it highly authentic and reliable. Readers are provided with deep analysis of historical and future market scenarios to get sound understanding of market competition and other important aspects. The report offers exhaustive research on market dynamics, key segments, leading players, and different regional markets. It is a complete package of thorough analysis and research on the global Liquid Biopsy Products market.

The global market for Liquid Biopsy Products was estimated to be worth US$ 5142 million in 2024 and is forecast to a readjusted size of US$ 11449 million by 2031 with a CAGR of 12.4% during the forecast period 2025-2031.

Get PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.in/request-sample/pharma-healthcare-liquid-biopsy-products-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Liquid biopsy products refer to a category of in vitro diagnostic tools that non-invasively analyze biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes from blood, urine, or other body fluids for cancer screening, diagnosis, treatment monitoring, and recurrence prediction. These products span key steps such as sample collection, preservation, nucleic acid extraction, target detection, and data interpretation. Compared to traditional tissue biopsy, liquid biopsy offers advantages in safety, repeatability, and applicability across various cancer types, making it increasingly adopted in clinical settings and showing great potential in precision and personalized medicine.

The rapid global advancement of precision medicine and rising cancer incidence form a strong foundation for liquid biopsy adoption. National healthcare systems are increasingly incorporating liquid biopsy into cancer screening and targeted therapy workflows. The declining cost of next-generation sequencing (NGS) and enhanced interpretation capabilities through AI are accelerating product entry into multi-cancer detection and multicenter clinical validation.

Despite increasing technological maturity, liquid biopsy still faces challenges in balancing sensitivity and specificity, especially for early-stage cancer detection. Non-uniform standards in sample processing and reagent quality across upstream and downstream components complicate clinical translation. Regulatory hurdles around privacy and bioethics remain significant barriers for global expansion. Broker analyses highlight that most revenue still stems from research-grade orders, and wider clinical adoption and reimbursement pathways require further development.

Demand for liquid biopsy is rapidly shifting from research use to routine clinical applications. Monitoring therapeutic response and early relapse detection in high-incidence cancers-such as lung, breast, and colorectal-are driving hospital procurement. Collaboration between biotech companies and hospitals is deepening, with joint labs and multicenter studies becoming the norm. Annual reports also reflect growing patient awareness and preference for non-invasive testing, spurring product expansion into home-testing and mobile diagnostic scenarios.

Drivers and Restraints-

The report explains the drivers shaping the future of the Liquid Biopsy Products market. It evaluates the various forces that are expected to create a positive influence on the overall market. Analysts have studied the investments in research and development of products and technologies that are expected to give the players a definite boost. Furthermore, researchers have also included an analysis of the changing consumer behavior that is projected to impact the supply and demand cycles present in the global Liquid Biopsy Products market. Evolving per capita earnings, improving economic statuses, and emerging trends have all been studied in this research report.

The research report also explains the potential restraints present in the global Liquid Biopsy Products market. It evaluates the aspects that are likely to hamper the market growth in the near future. In addition to this assessment, it also provides a list of opportunities that could prove lucrative to the overall market. Analysts provide solutions for turning threats and restraints into successful opportunities in the coming years.

The competitive landscape of the global Liquid Biopsy Products market is broadly studied in the report with large focus on recent developments, future plans of top players, and key growth strategies adopted by them. The analysts authoring the report have profiled almost every major player of the global Liquid Biopsy Products market and thrown light on their crucial business aspects such as production, areas of operation, and product portfolio. All companies analyzed in the report are studied on the basis of vital factors such as market share, market growth, company size, production volume, revenue, and earnings.

Key Players Mentioned in the Global Liquid Biopsy Products Market Research Report:

Roche
Illumina
Qiagen
Guardant Health
MDxHealth
Pathway Genomics
NeoGenomics Laboraories
Novogen
BGI
Myriad Genetics
Adaptive Biotechnologies
Biocept
Angle plc
Exact Sciences
Natera
Freenome
Aide Bio
Thermo Fisher Scientific

The report offers great insights into important segments of the global Liquid Biopsy Products market while concentrating on their CAGR, market size, market share, and future growth potential. The global Liquid Biopsy Products market is mainly segmented according to type of product, application, and region. Each segment in these categories is extensively researched to become familiar with their growth prospects and key trends. Segmental analysis is highly important to identify key growth pockets of a global market. The report provides specific information on the market growth and demand of different products and applications to help players to focus on profitable areas of the global Liquid Biopsy Products market.

Details of Liquid Biopsy Products Market Segmentation: -

Segment by Type:

CTCs
ctDNA
Exosomes

Segment by Application:

Hospitals and Clinics
Third-party Laboratories
Other

Research Methodology

This report has been compiled using latest primary and secondary research methodologies such as data triangulation, qualitative and quantitative analysis, and top-down and bottom-up approaches. The researchers also referred to reliable secondary sources for collecting important data and statistics. All the findings of the research study have been verified and revalidated with the help of authentic primary sources.

The researchers create a unique model and customize it for each research study. Their market forecasts are based on the industry-best combination of domain expertise, industry knowledge and experience, technological analysis, and economic tools. Technological market models are generally adopted for long-term market forecasting, whereas econometric models are adopted for short-term forecasting. The researchers were provided with advanced analysis tools at the time of the preparation of the report.

Report Objectives

(1) To carefully analyze and estimate the size of the global Liquid Biopsy Products market

(2) To clearly segment the global Liquid Biopsy Products market and estimate the market size of the segments

(3) To provide details about key strategies adopted by leading players of the global Liquid Biopsy Products market

(4) To help readers understand current and future market scenarios

(5) To provide information about latest trends of the global Liquid Biopsy Products market and its key segments

(6) To assess the contribution of each region or country to the global Liquid Biopsy Products market

(7) To provide information on important drivers, restraints, and opportunities of the global Liquid Biopsy Products market

(8) To accurately calculate the market shares of key segments, regions, and companies in the global Liquid Biopsy Products market

Request Pre-Order Enquiry or Customized Research on This Report: https://www.qyresearch.in/pre-order-inquiry/pharma-healthcare-liquid-biopsy-products-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Table of Content

"1 Market Overview
1.1 Liquid Biopsy Products Product Introduction
1.2 Global Liquid Biopsy Products Market Size Forecast (2020-2031)
1.3 Liquid Biopsy Products Market Trends & Drivers
1.3.1 Liquid Biopsy Products Industry Trends
1.3.2 Liquid Biopsy Products Market Drivers & Opportunity
1.3.3 Liquid Biopsy Products Market Challenges
1.3.4 Liquid Biopsy Products Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Liquid Biopsy Products Players Revenue Ranking (2024)
2.2 Global Liquid Biopsy Products Revenue by Company (2020-2025)
2.3 Key Companies Liquid Biopsy Products Manufacturing Base Distribution and Headquarters
2.4 Key Companies Liquid Biopsy Products Product Offered
2.5 Key Companies Time to Begin Mass Production of Liquid Biopsy Products
2.6 Liquid Biopsy Products Market Competitive Analysis
2.6.1 Liquid Biopsy Products Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Liquid Biopsy Products Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liquid Biopsy Products as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CTCs
3.1.2 ctDNA
3.1.3 Exosomes
3.2 Global Liquid Biopsy Products Sales Value by Type
3.2.1 Global Liquid Biopsy Products Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Liquid Biopsy Products Sales Value, by Type (2020-2031)
3.2.3 Global Liquid Biopsy Products Sales Value, by Type (%) (2020-2031)
4 Segmentation by Sample
4.1 Introduction by Sample
4.1.1 Blood Sample
4.1.2 Urine Sample
4.1.3 Other
4.2 Global Liquid Biopsy Products Sales Value by Sample
4.2.1 Global Liquid Biopsy Products Sales Value by Sample (2020 VS 2024 VS 2031)
4.2.2 Global Liquid Biopsy Products Sales Value, by Sample (2020-2031)
4.2.3 Global Liquid Biopsy Products Sales Value, by Sample (%) (2020-2031)
5 Segmentation by Application
5.1 Introduction by Application
5.1.1 Hospitals and Clinics
5.1.2 Third-party Laboratories
5.1.3 Other
5.2 Global Liquid Biopsy Products Sales Value by Application
5.2.1 Global Liquid Biopsy Products Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Liquid Biopsy Products Sales Value, by Application (2020-2031)
5.2.3 Global Liquid Biopsy Products Sales Value, by Application (%) (2020-2031)
6 Segmentation by Region
6.1 Global Liquid Biopsy Products Sales Value by Region
6.1.1 Global Liquid Biopsy Products Sales Value by Region: 2020 VS 2024 VS 2031
6.1.2 Global Liquid Biopsy Products Sales Value by Region (2020-2025)
6.1.3 Global Liquid Biopsy Products Sales Value by Region (2026-2031)
6.1.4 Global Liquid Biopsy Products Sales Value by Region (%), (2020-2031)
6.2 North America
6.2.1 North America Liquid Biopsy Products Sales Value, 2020-2031
6.2.2 North America Liquid Biopsy Products Sales Value by Country (%), 2024 VS 2031
6.3 Europe
6.3.1 Europe Liquid Biopsy Products Sales Value, 2020-2031
6.3.2 Europe Liquid Biopsy Products Sales Value by Country (%), 2024 VS 2031
6.4 Asia Pacific
6.4.1 Asia Pacific Liquid Biopsy Products Sales Value, 2020-2031
6.4.2 Asia Pacific Liquid Biopsy Products Sales Value by Region (%), 2024 VS 2031
6.5 South America
6.5.1 South America Liquid Biopsy Products Sales Value, 2020-2031
6.5.2 South America Liquid Biopsy Products Sales Value by Country (%), 2024 VS 2031
6.6 Middle East & Africa
6.6.1 Middle East & Africa Liquid Biopsy Products Sales Value, 2020-2031
6.6.2 Middle East & Africa Liquid Biopsy Products Sales Value by Country (%), 2024 VS 2031
7 Segmentation by Key Countries/Regions
7.1 Key Countries/Regions Liquid Biopsy Products Sales Value Growth Trends, 2020 VS 2024 VS 2031
7.2 Key Countries/Regions Liquid Biopsy Products Sales Value, 2020-2031
7.3 United States
7.3.1 United States Liquid Biopsy Products Sales Value, 2020-2031
7.3.2 United States Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
7.3.3 United States Liquid Biopsy Products Sales Value by Application, 2024 VS 2031
7.4 Europe
7.4.1 Europe Liquid Biopsy Products Sales Value, 2020-2031
7.4.2 Europe Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
7.4.3 Europe Liquid Biopsy Products Sales Value by Application, 2024 VS 2031
7.5 China
7.5.1 China Liquid Biopsy Products Sales Value, 2020-2031
7.5.2 China Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
7.5.3 China Liquid Biopsy Products Sales Value by Application, 2024 VS 2031
7.6 Japan
7.6.1 Japan Liquid Biopsy Products Sales Value, 2020-2031
7.6.2 Japan Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
7.6.3 Japan Liquid Biopsy Products Sales Value by Application, 2024 VS 2031
7.7 South Korea
7.7.1 South Korea Liquid Biopsy Products Sales Value, 2020-2031
7.7.2 South Korea Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
7.7.3 South Korea Liquid Biopsy Products Sales Value by Application, 2024 VS 2031
7.8 Southeast Asia
7.8.1 Southeast Asia Liquid Biopsy Products Sales Value, 2020-2031
7.8.2 Southeast Asia Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
7.8.3 Southeast Asia Liquid Biopsy Products Sales Value by Application, 2024 VS 2031
7.9 India
7.9.1 India Liquid Biopsy Products Sales Value, 2020-2031
7.9.2 India Liquid Biopsy Products Sales Value by Type (%), 2024 VS 2031
7.9.3 India Liquid Biopsy Products Sales Value by Application, 2024 VS 2031
8 Company Profiles
8.1 Roche
8.1.1 Roche Profile
8.1.2 Roche Main Business
8.1.3 Roche Liquid Biopsy Products Products, Services and Solutions
8.1.4 Roche Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.1.5 Roche Recent Developments
8.2 Illumina
8.2.1 Illumina Profile
8.2.2 Illumina Main Business
8.2.3 Illumina Liquid Biopsy Products Products, Services and Solutions
8.2.4 Illumina Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.2.5 Illumina Recent Developments
8.3 Qiagen
8.3.1 Qiagen Profile
8.3.2 Qiagen Main Business
8.3.3 Qiagen Liquid Biopsy Products Products, Services and Solutions
8.3.4 Qiagen Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.3.5 Qiagen Recent Developments
8.4 Guardant Health
8.4.1 Guardant Health Profile
8.4.2 Guardant Health Main Business
8.4.3 Guardant Health Liquid Biopsy Products Products, Services and Solutions
8.4.4 Guardant Health Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.4.5 Guardant Health Recent Developments
8.5 MDxHealth
8.5.1 MDxHealth Profile
8.5.2 MDxHealth Main Business
8.5.3 MDxHealth Liquid Biopsy Products Products, Services and Solutions
8.5.4 MDxHealth Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.5.5 MDxHealth Recent Developments
8.6 Pathway Genomics
8.6.1 Pathway Genomics Profile
8.6.2 Pathway Genomics Main Business
8.6.3 Pathway Genomics Liquid Biopsy Products Products, Services and Solutions
8.6.4 Pathway Genomics Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.6.5 Pathway Genomics Recent Developments
8.7 NeoGenomics Laboraories
8.7.1 NeoGenomics Laboraories Profile
8.7.2 NeoGenomics Laboraories Main Business
8.7.3 NeoGenomics Laboraories Liquid Biopsy Products Products, Services and Solutions
8.7.4 NeoGenomics Laboraories Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.7.5 NeoGenomics Laboraories Recent Developments
8.8 Novogen
8.8.1 Novogen Profile
8.8.2 Novogen Main Business
8.8.3 Novogen Liquid Biopsy Products Products, Services and Solutions
8.8.4 Novogen Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.8.5 Novogen Recent Developments
8.9 BGI
8.9.1 BGI Profile
8.9.2 BGI Main Business
8.9.3 BGI Liquid Biopsy Products Products, Services and Solutions
8.9.4 BGI Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.9.5 BGI Recent Developments
8.10 Myriad Genetics
8.10.1 Myriad Genetics Profile
8.10.2 Myriad Genetics Main Business
8.10.3 Myriad Genetics Liquid Biopsy Products Products, Services and Solutions
8.10.4 Myriad Genetics Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.10.5 Myriad Genetics Recent Developments
8.11 Adaptive Biotechnologies
8.11.1 Adaptive Biotechnologies Profile
8.11.2 Adaptive Biotechnologies Main Business
8.11.3 Adaptive Biotechnologies Liquid Biopsy Products Products, Services and Solutions
8.11.4 Adaptive Biotechnologies Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.11.5 Adaptive Biotechnologies Recent Developments
8.12 Biocept
8.12.1 Biocept Profile
8.12.2 Biocept Main Business
8.12.3 Biocept Liquid Biopsy Products Products, Services and Solutions
8.12.4 Biocept Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.12.5 Biocept Recent Developments
8.13 Angle plc
8.13.1 Angle plc Profile
8.13.2 Angle plc Main Business
8.13.3 Angle plc Liquid Biopsy Products Products, Services and Solutions
8.13.4 Angle plc Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.13.5 Angle plc Recent Developments
8.14 Exact Sciences
8.14.1 Exact Sciences Profile
8.14.2 Exact Sciences Main Business
8.14.3 Exact Sciences Liquid Biopsy Products Products, Services and Solutions
8.14.4 Exact Sciences Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.14.5 Exact Sciences Recent Developments
8.15 Natera
8.15.1 Natera Profile
8.15.2 Natera Main Business
8.15.3 Natera Liquid Biopsy Products Products, Services and Solutions
8.15.4 Natera Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.15.5 Natera Recent Developments
8.16 Freenome
8.16.1 Freenome Profile
8.16.2 Freenome Main Business
8.16.3 Freenome Liquid Biopsy Products Products, Services and Solutions
8.16.4 Freenome Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.16.5 Freenome Recent Developments
8.17 Aide Bio
8.17.1 Aide Bio Profile
8.17.2 Aide Bio Main Business
8.17.3 Aide Bio Liquid Biopsy Products Products, Services and Solutions
8.17.4 Aide Bio Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.17.5 Aide Bio Recent Developments
8.18 Thermo Fisher Scientific
8.18.1 Thermo Fisher Scientific Profile
8.18.2 Thermo Fisher Scientific Main Business
8.18.3 Thermo Fisher Scientific Liquid Biopsy Products Products, Services and Solutions
8.18.4 Thermo Fisher Scientific Liquid Biopsy Products Revenue (US$ Million) & (2020-2025)
8.18.5 Thermo Fisher Scientific Recent Developments
9 Industry Chain Analysis
9.1 Liquid Biopsy Products Industrial Chain
9.2 Liquid Biopsy Products Upstream Analysis
9.2.1 Key Raw Materials
9.2.2 Raw Materials Key Suppliers
9.2.3 Manufacturing Cost Structure
9.3 Midstream Analysis
9.4 Downstream Analysis (Customers Analysis)
9.5 Sales Model and Sales Channels
9.5.1 Liquid Biopsy Products Sales Model
9.5.2 Sales Channel
9.5.3 Liquid Biopsy Products Distributors
10 Research Findings and Conclusion
11 Appendix
11.1 Research Methodology
11.1.1 Methodology/Research Approach
11.1.1.1 Research Programs/Design
11.1.1.2 Market Size Estimation
11.1.1.3 Market Breakdown and Data Triangulation
11.1.2 Data Source
11.1.2.1 Secondary Sources
11.1.2.2 Primary Sources
11.2 Author Details
11.3 Disclaimer

Contact US

Ankit Jain - Director, Global Digital Marketing

QY Research, INC.
India Office -
315Work Avenue, Raheja Woods, Kalyani Nagar,
Pune, Maharashtra 411006, India
Web - https://www.qyresearch.in
Email- ankit@qyresearch.com

About US:

QYResearch is a leading global market research and consulting company established in 2007. With over 17 years' experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability.

This release was published on openPR.